FDA approves Mylotarg for treatment of acute myeloid leukemia

By Newsroom America Feeds at 1 Sep 2017

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574507.htm

Categories:
Tags:

[D] [Digg] [FB] [R] [SU] [Tweet] [G]

NEWSMAIL